PROTARA THERAPEUT.DL-001
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more
PROTARA THERAPEUT.DL-001 (1KPA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PROTARA THERAPEUT.DL-001 (1KPA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PROTARA THERAPEUT.DL-001 - Net Assets Trend (None–None)
This chart illustrates how PROTARA THERAPEUT.DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PROTARA THERAPEUT.DL-001 (None–None)
The table below shows the annual net assets of PROTARA THERAPEUT.DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PROTARA THERAPEUT.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PROTARA THERAPEUT.DL-001 Competitors by Market Cap
The table below lists competitors of PROTARA THERAPEUT.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Solrom Holdings Ltd
TA:SLRM
|
$164.72 Million |
|
Liaoning Shidai Wanheng Co Ltd
SHG:600241
|
$164.81 Million |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
$164.81 Million |
|
Pilani Investment and Industries Corporation Limited
NSE:PILANIINVS
|
$164.88 Million |
|
Zedcor Inc.
PINK:ZDCAF
|
$164.65 Million |
|
Jiangxi Sunshine Dairy Co Ltd
SHE:001318
|
$164.61 Million |
|
Richards Packaging Income Fund
PINK:RPKIF
|
$164.61 Million |
|
Shanghai Tianyong Engineering Co Ltd
SHG:603895
|
$164.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PROTARA THERAPEUT.DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PROTARA THERAPEUT.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PROTARA THERAPEUT.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PROTARA THERAPEUT.DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PROTARA THERAPEUT.DL-001 (1KPA) | €- | N/A | N/A | $164.66 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |